Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.

Huang TT, Su JC, Liu CY, Shiau CW, Chen KF.

Int J Mol Sci. 2017 Jun 8;18(6). pii: E1234. doi: 10.3390/ijms18061234. Review.

2.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466.

3.

Distinct signaling programs control human hematopoietic stem cell survival and proliferation.

Knapp DJ, Hammond CA, Aghaeepour N, Miller PH, Pellacani D, Beer PA, Sachs K, Qiao W, Wang W, Humphries RK, Sauvageau G, Zandstra PW, Bendall SC, Nolan GP, Hansen C, Eaves CJ.

Blood. 2017 Jan 19;129(3):307-318. doi: 10.1182/blood-2016-09-740654. Epub 2016 Nov 8.

4.

The Role of p-STAT3 as a Prognostic and Clinicopathological Marker in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Ji K, Zhang M, Chu Q, Gan Y, Ren H, Zhang L, Wang L, Li X, Wang W.

PLoS One. 2016 Aug 9;11(8):e0160125. doi: 10.1371/journal.pone.0160125. eCollection 2016.

5.

Docosahexaenoic acid inhibits 12-O-tetradecanoylphorbol-13- acetate-induced fascin-1-dependent breast cancer cell migration by suppressing the PKCδ- and Wnt-1/β-catenin-mediated pathways.

Lii CK, Chang JW, Chen JJ, Chen HW, Liu KL, Yeh SL, Wang TS, Liu SH, Tsai CH, Li CC.

Oncotarget. 2016 May 3;7(18):25162-79. doi: 10.18632/oncotarget.7301.

6.

Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis.

Hox V, O'Connell MP, Lyons JJ, Sackstein P, Dimaggio T, Jones N, Nelson C, Boehm M, Holland SM, Freeman AF, Tweardy DJ, Olivera A, Metcalfe DD, Milner JD.

J Allergy Clin Immunol. 2016 Jul;138(1):187-99. doi: 10.1016/j.jaci.2015.11.024. Epub 2016 Mar 2.

7.

Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.

Pramanik KC, Fofaria NM, Gupta P, Ranjan A, Kim SH, Srivastava SK.

Oncotarget. 2015 May 10;6(13):11561-74.

8.

Activation of Wnt/β-catenin signaling in Muller glia protects photoreceptors in a mouse model of inherited retinal degeneration.

Patel AK, Surapaneni K, Yi H, Nakamura RE, Karli SZ, Syeda S, Lee T, Hackam AS.

Neuropharmacology. 2015 Apr;91:1-12. doi: 10.1016/j.neuropharm.2014.11.015. Epub 2014 Dec 6.

9.

STAT3 paradoxically stimulates β-catenin expression but inhibits β-catenin function.

Ibrahem S, Al-Ghamdi S, Baloch K, Muhammad B, Fadhil W, Jackson D, Nateri AS, Ilyas M.

Int J Exp Pathol. 2014 Dec;95(6):392-400. doi: 10.1111/iep.12102. Epub 2014 Oct 28.

10.

STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer.

Nguyen AV, Wu YY, Lin EY.

World J Gastroenterol. 2014 Aug 14;20(30):10279-87. doi: 10.3748/wjg.v20.i30.10279. Review.

11.

STAT3: An Anti-Invasive Factor in Colorectal Cancer?

de Jong PR, Mo JH, Harris AR, Lee J, Raz E.

Cancers (Basel). 2014 Jul 3;6(3):1394-407. doi: 10.3390/cancers6031394.

12.

Concerted suppression of STAT3 and GSK3β is involved in growth inhibition of non-small cell lung cancer by Xanthatin.

Tao L, Fan F, Liu Y, Li W, Zhang L, Ruan J, Shen C, Sheng X, Zhu Z, Wang A, Chen W, Huang S, Lu Y.

PLoS One. 2013 Nov 28;8(11):e81945. doi: 10.1371/journal.pone.0081945. eCollection 2013.

13.

STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon.

Nguyen AV, Wu YY, Liu Q, Wang D, Nguyen S, Loh R, Pang J, Friedman K, Orlofsky A, Augenlicht L, Pollard JW, Lin EY.

Neoplasia. 2013 Sep;15(9):998-1008.

14.

Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.

Lin W, Zheng L, Zhuang Q, Zhao J, Cao Z, Zeng J, Lin S, Xu W, Peng J.

BMC Complement Altern Med. 2013 Jun 24;13:144. doi: 10.1186/1472-6882-13-144.

15.

β-catenin regulates innate and adaptive immunity in mouse liver ischemia-reperfusion injury.

Ke B, Shen XD, Kamo N, Ji H, Yue S, Gao F, Busuttil RW, Kupiec-Weglinski JW.

Hepatology. 2013 Mar;57(3):1203-14. doi: 10.1002/hep.26100. Epub 2013 Feb 7.

16.

The Wnt/β-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells.

Fragoso MA, Patel AK, Nakamura RE, Yi H, Surapaneni K, Hackam AS.

PLoS One. 2012;7(10):e46892. doi: 10.1371/journal.pone.0046892. Epub 2012 Oct 4.

17.

Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells.

Hamilton KE, Simmons JG, Ding S, Van Landeghem L, Lund PK.

Mol Cancer Res. 2011 Dec;9(12):1718-31. doi: 10.1158/1541-7786.MCR-10-0210. Epub 2011 Oct 12.

18.

Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.

Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S.

JAMA. 2011 Apr 27;305(16):1685-94. doi: 10.1001/jama.2011.513.

19.

STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S.

Clin Cancer Res. 2011 Mar 15;17(6):1452-62. doi: 10.1158/1078-0432.CCR-10-2694. Epub 2011 Feb 10.

20.

Cytokines, inflammation and colon cancer.

Klampfer L.

Curr Cancer Drug Targets. 2011 May;11(4):451-64. Review.

Supplemental Content

Support Center